Trial Profile
Non-interventional, Prospective, Long-term Safety Data Collection of Zarzio / Filgrastim HEXAL in Healthy Unrelated Stem Cell Donors Undergoing Peripheral Blood Progenitor Cell Mobilization
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary)
- Indications Stem cell mobilisation
- Focus Adverse reactions
- Acronyms SMART
- Sponsors HEXAL; Sandoz
- 10 Oct 2014 New trial record